منابع مشابه
TFOS DEWS II iatrogenic report.
Dry eye can be caused by a variety of iatrogenic interventions. The increasing number of patients looking for eye care or cosmetic procedures involving the eyes, together with a better understanding of the pathophysiological mechanisms of dry eye disease (DED), have led to the need for a specific report about iatrogenic dry eye within the TFOS DEWS II. Topical medications can cause DED due to t...
متن کاملTFOS DEWS II Management and Therapy Report.
The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Follow...
متن کاملTFOS DEWS II Introduction.
J. Daniel Nelson, MD a, b, , Jennifer P. Craig, MCOptom, PhD , Esen K. Akpek MD , Dimitri T. Azar, MD , Carlos Belmonte, MD, PhD f, , Anthony J. Bron, FRCOphth, FMedSci h, , Janine A. Clayton, MD , Murat Dogru, MD, PhD k, , Harminder S. Dua, MD, PhD , Gary N. Foulks, MD , Jos e A.P. Gomes, MD, PhD , Katherine M. Hammitt, MA , Juha Holopainen, MD, PhD , Lyndon Jones, FCOptom, PhD , Choun-Ki Joo,...
متن کاملTFOS DEWS II Report Executive Summary.
This article presents an Executive Summary of the conclusions and recommendations of the 10-chapter TFOS DEWS II report. The entire TFOS DEWS II report was published in the July 2017 issue of The Ocular Surface. A downloadable version of the document and additional material, including videos of diagnostic and management techniques, are available on the TFOS website: www.TearFilm.org.
متن کاملTFOS DEWS II Clinical Trial Design Report.
The development of novel therapies for Dry Eye Disease (DED) is formidable, and relatively few treatments evaluated have been approved for marketing. In this report, the Subcommittee reviewed challenges in designing and conducting quality trials, with special reference to issues in trials in patients with DED and present the regulatory perspective on DED therapies. The Subcommittee reviewed the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Ocular Surface
سال: 2017
ISSN: 1542-0124
DOI: 10.1016/j.jtos.2017.05.002